


**Tender Reference no.-BMSIC/DRUG/17-11**

S.N.	Technical Eligibility Criteria as per NIT	<p><b>Firm Name - Unicare (India) Limited</b>  <b>Corporate Address:- C-677, New Friends Colony, New Delhi-110025</b>  <b>Manufacturer Address:-C-21, 22 &amp; 23, Sector-3, Noida-201301, Distt. Gautambudhnagar (U.P.)</b></p>																		
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	<p>(a) Self attested copy of Certificate of Incorporation of Unicare ( India ) Private Limited, No. 10642 dated 14/07/1980 submitted. (Pg. No. 21)                      (b) Self attested copy of Certificate of Change of name, submitted by which name of Unicare (India) Pvt. Ltd. has changed to Unicare India Limited on 20/03/2013. (Pg. No. 22)                      (c) Self attested copy of Memorandum and Article of Association is submitted. (Pg. No. 23 )                      (d) Self Attested Copy of memorandum of Association is Submitted Only ( Page No.12-20).                      (e) Bidder information/Bidder details submitted as per annexure V of NIT. ( Page No. 74)                      (f) Self attested copy of Article of Association is submitted . ( Page No. 75-101 )                      (g) Self attested copy of subscriber detail attached by which it is clear that Mr. Abdul Mateen and Abdul Rasheed are the subscriber. (pg. no.-12)  <b>Note:- 1)Minimum seven subscriber required for public ltd. company.</b>  <b>2)Subscriber detail attached with AOA &amp; MOA is of year 1980 whereas the fresh certificate of incorporation is of year 2013.</b></p>																		
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	<p>(a) Notarised Copy of Authorization Letter Submitted in favour of Mr. Rupesh Kumar duly Authorised by Managing Director, Mr. Abdul Mateen, on non judicial Stamp paper of Rs10/- ( Page No. 8)  <b>Note (1) Copy of Board Resolution is not submitted.</b></p>																		
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (c)	<p>Self attested copy of list of items quoted as per Annexure III submitted. (Pg. No. 48-49)                      No. of Item quoted- 5 ( Five)</p> <table border="0"> <thead> <tr> <th data-bbox="908 738 1052 771">NIT S.N.</th> <th data-bbox="1052 738 1579 771">Specification of Quoted Product</th> <th data-bbox="1579 738 2445 771">Specification as per NIT</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Chloroquin Phosphate Tablet I.P 250 mg</td> <td>Chloroquin Phosphate Tablet I.P 250 mg</td> </tr> <tr> <td>7.</td> <td>ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate IP + ( Sulfadoxine IP+ Pyrimethamine) For (i) 1 to 4 year children</td> <td>ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 1 to 4 year children</td> </tr> <tr> <td>8.</td> <td>ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children</td> <td>ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children</td> </tr> <tr> <td>9.</td> <td>ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children</td> <td>ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children</td> </tr> <tr> <td>10.</td> <td>ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above</td> <td>ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above</td> </tr> </tbody> </table>	NIT S.N.	Specification of Quoted Product	Specification as per NIT	1.	Chloroquin Phosphate Tablet I.P 250 mg	Chloroquin Phosphate Tablet I.P 250 mg	7.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate IP + ( Sulfadoxine IP+ Pyrimethamine) For (i) 1 to 4 year children	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 1 to 4 year children	8.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children	9.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children	10.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above
NIT S.N.	Specification of Quoted Product	Specification as per NIT																		
1.	Chloroquin Phosphate Tablet I.P 250 mg	Chloroquin Phosphate Tablet I.P 250 mg																		
7.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate IP + ( Sulfadoxine IP+ Pyrimethamine) For (i) 1 to 4 year children	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 1 to 4 year children																		
8.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 5 to 8 year children																		
9.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 9 to 14 year children																		
10.	ACT Combi pack For Different Age Group (Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above	ACT Combi pack For Different Age Group ( Artemisinin based combination Therapy or Artesunate + ( Sulfadoxine- + Pyrimethamine) For (i) 15 years and Above																		

4	<ul style="list-style-type: none"> <li>• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f).</li> <li>• Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f).</li> <li>• Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f).</li> <li>• In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.</li> <li>• Market standing certificate &amp; Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organization). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing &amp; Market standing clause will be relaxed.</li> <li>• For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.</li> <li>• FFS (Flow Fill &amp; Seal Process) Technology will be accepted wherever applicable.</li> </ul> <p>Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)</p>	<p>(a) Self attested Manufacturing Licence No. 3 of 1984 form on form 25 and 3/SC/P of 1984 on 28 is Submitted Valid from 03/01/1984 to 31/12/1985 in the name of <b>Unicare (India) Pvt. Ltd.</b> ( page No.46-47) whereas, firm has bid as <b>Unicare (India) Ltd.</b></p> <p>(b) Self attested A letter No. Drug/1666/5137 dt.14/08/2013 informing to drugs department regarding Change of Name of Company from Unicare (India) Pvt. Ltd to Unicare India Ltd.</p> <p>(c) Self attested Renewal of Licence of Unicare (India) Pvt. Ltd. from on form 26 from 01/01/2012 to 31/12/2016 and from 01/01/2017 to 31/12/2021 is submitted along with Approved products List. ( Page No.36-44)</p> <p>(d) Self attested Approved products List for Quoted drugs and copy of renewal submitted ( Page No. 36-38 and 40-43)</p> <p>(e) Firm has marked following drugs in bid as below.</p> <table border="1"> <thead> <tr> <th>S. no.-</th> <th>NIT Sr. no.</th> <th>Product Detail</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>6 (i) (0 to 1 year)</td> <td>Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 25 mg &amp; 1 tablet of Primethaine &amp; Sulphadoxine Tablets IP (12.5 mg + 250 mg)</td> </tr> <tr> <td>2.</td> <td>6 (ii) (1 to 4 year)</td> <td>Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 50 mg &amp; 1 tablet of Primethaine &amp; Sulphadoxine Tablets IP (25 mg + 500 mg)</td> </tr> <tr> <td>3.</td> <td>6 (iii) (5 to 8 year)</td> <td>Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 100 mg &amp; 1 tablet of Primethaine &amp; Sulphadoxine Tablets IP (37.5 mg + 750 mg)</td> </tr> <tr> <td>4.</td> <td>6 (iv) (9 to 14 year)</td> <td>Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- 3 tab of Artesunate Tablets 150 mg &amp; 2 tablet of Primethaine &amp; Sulphadoxine Tablets IP (25 mg + 500 mg)</td> </tr> <tr> <td>5.</td> <td>6 (v) (15 years)</td> <td>Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 200 mg &amp; 1 tablet of Primethaine &amp; Sulphadoxine Tablets IP (25 mg + 500 mg)</td> </tr> <tr> <td>6.</td> <td>NIT Sr. no.-1</td> <td>Chloroquine Phosphate Tablet IP 250 mg. (equivalent to 155 mg Chloroquine base)</td> </tr> </tbody> </table> <p><b>Note:- For NIT sr. no. -1, there is no IP specification marked for colourant Titanium Dioxide in product approval and for NIT sr. no.-6 (iii) dose need to be verified.</b> Firm has marked 6 (i) but has not quoted in Annexure-III or anywhere in the document.</p>	S. no.-	NIT Sr. no.	Product Detail	1.	6 (i) (0 to 1 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 25 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (12.5 mg + 250 mg)	2.	6 (ii) (1 to 4 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 50 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	3.	6 (iii) (5 to 8 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 100 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (37.5 mg + 750 mg)	4.	6 (iv) (9 to 14 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- 3 tab of Artesunate Tablets 150 mg & 2 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	5.	6 (v) (15 years)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 200 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	6.	NIT Sr. no.-1	Chloroquine Phosphate Tablet IP 250 mg. (equivalent to 155 mg Chloroquine base)
S. no.-	NIT Sr. no.	Product Detail																					
1.	6 (i) (0 to 1 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 25 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (12.5 mg + 250 mg)																					
2.	6 (ii) (1 to 4 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- Artesunate Tablets 50 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)																					
3.	6 (iii) (5 to 8 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 100 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (37.5 mg + 750 mg)																					
4.	6 (iv) (9 to 14 year)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:- 3 tab of Artesunate Tablets 150 mg & 2 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)																					
5.	6 (v) (15 years)	Combi Blister pack of Artesunate Tablet IP, Pyrimethamine Sulphadoxine Tablets Each Kit contains:-3 tablets of Artesunate Tablets 200 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)																					
6.	NIT Sr. no.-1	Chloroquine Phosphate Tablet IP 250 mg. (equivalent to 155 mg Chloroquine base)																					
5	<p>In case of Importer, the bidder (importer) firm must have minimum three years old valid import license of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender. As per Clause 3(g)</p>	<p>Bidder stated that Import License is not applicable ( Page No. 53 )</p>																					
6	<p>Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)</p>	<p>Self attested copy of Manufacturing and Marketing certificate No. Drug/1666/3531, dated 06/06/2017 issued by Drugs Licensing and Controlling Authority, Uttar Pradesh, in favour of M/s Unicare (India) Ltd. where as mentioned that non of the following drug (attached List) permissions have been cancelled in the last 3-Years.( Page No. 24-35)</p>																					
7	<p>Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).</p>	<p>(a) Self attested copy of Non-Conviction Certificate No. Drug/1666/3156 dated 16/05/2017 issued by Drugs Licensing and controlling Authority, Uttar Pradesh in the name of M/s Unicare India Ltd. holding Mfg Licence 03/SC/P of 1984 On form 28, Licence No.-03 of 1984 on form 25 and Licence No.1/RPL/1991 on form 25B (Pg. No. 10-11)</p>																					

one hand      

8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. As per clause 3(j).	Self attested copy of GMP Compliance Certificate No. Drug/1666/566 Dated 08/01/2017 valid upto 17/01/2018 issued by Drugs Licencing and controlling Authority, Lucknow, Uttar Pradesh Submitted (Pg. No. 56) Self attested copy of GMP Compliance Certificate No. Drug/1666/ Dated 06/06/2017 valid upto 15/05/2019 issued by Drugs Licencing and controlling Authority, Lucknow, Uttar Pradesh Submitted (Pg. No. 54)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importers will have also to submit Invoices/Evidence of import in items of said product with quantity details. As per Clause 3(k).	(a) Self attested copy of Production Capacity Letter No. Drug/1666/309 Dt.15.01.2013, Duly signed by Drugs Licencing cum Controlling Authority, Uttar Pradesh, section wise submitted by Unicure (India) Pvt. Ltd while tender is quoted by Unicure India Ltd. ( Page No.6-7) <b>Note- production capacity letter is almost 4-Year Old. Production Capacity certificate in the Name of Unicure ( India ) Pvt. Ltd. While tender is quoted by Unicure India Ltd. ( Page No. 6-7)</b>
10	An affidavit (with stamp) sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Self attested Notarised copy of affidavit for Non Blacklisting as per Annexure II of NIT is submitted duly signed by Authorised signatory, Mr. Rupesh Kumar. List of Quoted product is mentioned in the affidavit. (Pg. No. 71-72) <b>Note:-</b>
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	BG No-"A89GOPG173000003" dt.27/10/2017 of Canara Bank of Rs.1,00,000/- Valid Till 24/04/2018 Page No-57-60
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	DD NO "704008" (Canara Bank) `10,000/ Page No-5
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	FY-2015-16 Rs.163.88 (in crore) Page No -62 Fy-2014-15 Rs.166.38 (in crore) Page No -65 FY-2013-14 Rs.132.64(in crore) Page No - 68
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	AY-2016-17 Page No-50 Ay-2015-16 Page No-51 AY-2014-15 Page No -52
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN No -"AAACU0405C" Page No -9
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	GSTIN No -"09AAACU0405C1ZZ" Page No-1 - 4 TIN No. under Value added tax 09265700053 CST No. ND-5003803
17	Affidavit (with stamp) declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Self attested copy of Notarised affidavit (Acceptance of Tender conditions) on date 02/11/2017 on non judicial Stamp Paper of Rs. 100/- submitted duly signed by Authorised signatory, Rupesh Kumar. (Page No. 70)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL, in compliance of letter No 1146(15) Dt-05.11.2016 of Health Department, Govt of Bihar . Inspite, some inadvertent discrepencies could have been crept in. Humble request to all concerned to bring to notice in due time if any discrepencies is observed for rectification.

one sheet ~~E. Laxmi~~ ~~PP~~ ~~Amr~~ ~~RK~~ ~~del~~ ~~AS~~  
(11-16)